NeuroSolutions appoints Sigma Aldrich for scale-up
Friday, 26 August, 2005
NeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year.
NSL-043 has previously been developed by a Japanese company as an antirheumatic drug which progressed to complete a phase III clinical trial, passing all toxicology screens and demonstrating it was suitable for oral use, however the development was halted at this stage due to a lack of efficacy. NeuroSolutions has since reprofiled the drug candidate and undertaken extensive pre-clinical tests to demonstrate NSL-043 is potentially effective in the treatment of neuropathic pain prior to commencing the planned phase I clinical trial.
Sigma Aldrich chemists will utilise previously documented process development procedures for the synthesis of NSL-043 and determine the most efficient process for producing sufficient quantities for the commencement of a phase I clinical trial and additional trials planned for 2006.
"We reviewed a number of UK companies because we wanted to make sure we were hands on -- the lead candidate will be manufactured in the UK by Sigma Aldrich," said NeuroDiscovery chairman David McAuliffe.
"We are going to start phase I clinical trials later this year and phase II next year and plan scale up to be completed in the next six to eight weeks. It is a well know synthesis route and there shouldn't be too many complications in production," said McAuliffe.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...